They have a bullish share price target on the company, which I'll get to shortly.

Biotech focused on bone and soft tissue repair

So what does the company actually do?

In their own words:

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications.

Now let's look at the company's recent full-year results release.

Orthocell generated $13.2 million in revenue for FY26, up 45%, but its net loss also increased, jumping 59% to $13.6 million.

Chief Executive Officer Paul Anderson said:

FY26 was an important step in Orthocell's evolution as a global regenerative medicine company, with record revenue and continued progress across established markets and selected international opportunities. We delivered record revenue of $13.2 million, up 45% on FY25, including a record June quarter of $3.8 million. Remplir and Striate were the principal drivers, supported by continued strength in Australia and growing contributions from the United States and other international markets.

Mr Anderson said Australia was the company's most established market and was expected to continue growing, while FY26 was the first full year of Remplir's availability in the US.

He said further re the US market:

We are very pleased with this first-year progress, while recognising that the path from surgeon interest to hospital approval, first use and repeat ordering can extend over several months. In FY27, our priority is to deepen adoption within the established footprint by investing in targeted sales, education and marketing initiatives that support distributors and surgeons as Remplir becomes part of routine clinical practice and repeat use grows.

Shares looking cheap according to broker

Bell Potter said in its note to clients that the US would be the market to watch.

They said:

US access expanded strongly in FY26, but revenue has yet to scale in line with the footprint. The key watchpoint now shifts to repeat utilisation and revenue conversion, which management has highlighted as a core FY27 priority. This is consistent with our prior view and leaves the broader thesis intact. We maintain our Buy (speculative) rating and reduce valuation to $1.13 from $1.19 following earnings adjustments.

Orthocell shares are currently changing hands for 72.5 cents. The company is valued at $196.1 million.

The post Bell Potter says this ASX biotech could rise 56% appeared first on The Motley Fool Australia.

With global headwinds impacting the ASX 200 this year, it could be an ideal time to allocate capital towards high upside stocks. 

The team at Bell Potter have identified two in particular that fit this criteria. 

Let's see what the broker is projecting. 

Orthocell Ltd (ASX: OCC)

Orthocell is an Australian-based, commercial-stage regenerative medicine company developing and commercialising collagen-based medical devices and autologous cell therapies for the repair and regeneration of bone and soft tissue.

The company leverages their proprietary collagen processing and manufacturing platform to produce implantable biomaterials designed to support tissue regeneration and functional recovery.

As is commonplace with small-cap shares, it has experienced some volatility in 2026. 

However, Bell Potter has a speculative buy rating on this ASX small-cap, suggesting it could rise by 40% in the next year. 

In a note released yesterday, Bell Potter said June-quarter revenue increased 19% QoQ to a record $3.8m (+36% pcp), reflecting continued strength across the established market.

The broker said the US rollout of Remplir is making good progress. 

The product is now available to around half of the US population through expanded distributor coverage. 

Hospital access is also growing, with approvals in 151 hospitals and more applications still under review. 

In simple terms, more hospitals are buying the company's nerve repair product Remplir, and more surgeons have started using it. 

However, sales growth has trailed hospital access growth, suggesting many surgeons are still trialling the product and are yet to commit.

Based on this guidance, Bell Potter has a 12-month price target of $1.19 on this ASX small-cap, indicating a 40% upside from current levels. 

Sky Metals Ltd (ASX: SKY)

Another ASX small-cap drawing a speculative buy rating is Sky Metals. 

Sky Metals engages in the acquisition, exploration, and development of mineral resources.

Its share price has rocketed 183% higher year to date, and Bell Potter believes the growth can continue. 

Bell Potter noted that Sky Metals has significantly increased the estimated size of its Tallebung project in New South Wales. 

The updated resource now contains much more tin and tungsten than previously estimated. The company has also identified its first silver resource. 

Much of the resource is now classified with higher confidence, making it more likely to be converted into mineable reserves.

Based on this guidance, the broker has placed a 12-month price target of $0.350 on this ASX small-cap, indicating 37% upside from current levels. 

The post 2 ASX small-caps with 40% upside appeared first on The Motley Fool Australia.

At the centre of the announcement is Remplir, Orthocell's nerve repair product, which continues to deliver strong clinical outcomes.

Strong treatment success rate

Orthocell reported an overall treatment success rate of 89.7% across 66 patients and 78 procedures in its ongoing real-world evidence study. That's a strong headline number with solid supporting evidence.

In motor nerve repair procedures, more than 90% of procedures resulted in functional muscle recovery. Meanwhile, in nerve decompression procedures (which are typically used to treat chronic pain, numbness, and tingling), 89% of patients experienced significant improvement or complete relief.

Importantly, these results were achieved across a broad patient group, covering different types of nerve injuries and age ranges. That kind of consistency suggests the product's effectiveness isn't limited to narrow use cases.

Just as critical is the safety profile. The study reported no post-treatment complications or adverse effects, reinforcing confidence for surgeons considering adoption.

Why this matters

For investors, the focus is on what this means commercially.

Orthocell is already seeing growing adoption, with more than 300 surgeons across over 220 hospitals in Australia using Remplir. Early traction is also building in the US, including procedures within a Department of Defense hospital network.

These are all emerging signs of real value being created, which can hopefully translate into repeat usage, broader adoption, and ultimately, strong revenue growth.

Orthocell is now pushing into larger markets, with US expansion underway and Europe and the UK firmly in its sights. Regulatory approval in those regions is targeted for 2026, which could significantly expand its addressable market.

If the current clinical outcomes continue to hold and surgeon adoption keeps building, Orthocell may be moving closer to that key inflection point where a promising product becomes a scalable commercial business.

Foolish bottom line

Orthocell's latest update strengthens the case that Remplir can be widely adopted. For investors, that's a critical datapoint, and if momentum continues, this could be the early stages of a much larger growth story.

The post This ASX biotech hit a 90% success rate. Can it unlock commercial growth? appeared first on The Motley Fool Australia.

This came following the company's Quarterly Activity Report.

Orthocell is a regenerative medicine company. The company is engaged in the development and commercialisation of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry.

What did Orthocell report?

The company released its Quarterly Report for the quarter ended 31 March 2026 yesterday. 

It reported: 

• Year-to-date (Q1–Q3 FY26) revenue of $9.4 million represents a 45% increase on the prior corresponding period
• March quarter revenue in line with the prior quarter, with US sales reaching $300k
• Total revenue of $3.2m

Speaking on the result, Orthocell CEO and MD, Paul Anderson, said: 

This quarter reflects continued strong progress in the commercialisation of Remplir, particularly in the United States, where we are seeing growing surgeon adoption and increasing revenue contribution.

The consistency of our revenue performance and the growth in key commercial metrics, including hospital uptake, surgeon utilisation and distributor expansion, is particularly encouraging. Notably, the acceleration in U.S. revenue in March provides early evidence of a potential inflection point as these commercial efforts begin to scale.

Investors were seemingly left wanting more, as they largely exited their positions in Orthocell shares on Monday. 

What did Bell Potter have to say?

Following the result, the team at Bell Potter released updated guidance on the company. 

The broker said the March quarter total revenue of $3.2m was flat QoQ (+45% pcp), which appears broadly consistent with softer seasonal conditions typically seen in calendar Q1. 

It also pointed to some lag on repeat ordering as first use surgeons evaluate product performance in their own case. 

The quarter also marked the first meaningful US revenue contribution, with $300k of Remplir revenue, including $170k generated in March alone.

Speculative buy rating for Orthocell shares

Orthocell shares closed yesterday at $0.955 per share, down 7.7%. 

However, Bell Potter maintained its speculative buy rating, while also increasing its price target to $1.240 (previously  A$1.150). 

From yesterday's closing price, this updated target indicates an upside of approximately 30%. 

We maintain our BUY (spec.) recommendation and raise our valuation to $1.24. While the military hospital access win represents a meaningful de-risking event, we expect uptake across these channels to take time to establish, with the greater earnings contribution likely to emerge over later years.

The post Are Orthocell shares a buy after crashing 7% yesterday? appeared first on The Motley Fool Australia.

With shares up 26% this week at the time of writing, and just days after securing access to major US military and veteran hospital networks, the company has already completed its first surgical case using Remplir within the system.

The announcement reinforces the view that Orthocell is beginning to convert strategic wins into real-world clinical use.

Early signs of execution

Earlier this week, Orthocell announced it had secured approval to supply Remplir into the U.S. Department of Defence (DoD) and Veterans Affairs (VA) hospital networks, which together span more than 220 hospitals.

Now, the company has followed through quickly, completing its first procedure at a military hospital in Ohio, and the speed matters. In medtech, there is often a long lag between approval and adoption, but Orthocell appears to be compressing that timeline significantly.

This suggests the company's groundwork in preparing for distribution was already well advanced before access was formally granted.

What did management say?

Managing Director Paul Anderson emphasised the importance of speed, noting that the milestone validates Orthocell's commercial strategy, surgeon engagement, and distribution capability.

He also highlighted that early uptake in military and veteran systems (where complex injuries are common) is an encouraging sign as the company expands activity across these hospitals.

The message is clear: access is only the first step, and Orthocell is now focused on execution.

Foolish bottom line

Orthocell's 26% rise this week reflects growing investor interest in its US opportunity. More importantly, the latest update shows the company moving beyond announcements and into delivery.

Early surgical adoption, just days after approval, suggests that Orthocell's US strategy is gaining traction. The next phase will be about consistency in turning initial traction into repeat usage and sustained revenue growth.

The post Orthocell caps 26% surge this week with first US Military Surgery appeared first on The Motley Fool Australia.

What did the company announce?

At the centre of the announcement is approval for Orthocell's nerve repair product, Remplir, to be used across the U.S. Department of Defence and Veterans Affairs (VA) hospital networks. This opens up access to more than 220 hospitals, including 51 military hospitals and 170 VA medical centres.

That is a potentially transformational development because it provides the company with the opportunity to serve large healthcare systems with consistent patient volumes and a clear need for advanced surgical solutions.

In addition, the nature of the demand matters as much as the quantity. Military and veteran healthcare systems disproportionately handle complex trauma cases, where nerve repair solutions like Remplir are highly relevant. The product has already been used in conflict-related injuries in Ukraine, offering real-world validation in high-intensity environments.

Equally important, Orthocell is not starting from scratch. It already has a U.S. distribution network spanning 17 states and access to more than 115 hospitals via prior approvals. That existing footprint should help accelerate adoption and reduce the lag between approval and revenue generation.

What did management say?

Managing Director Paul Anderson described the approval as "a significant milestone" and "a major step forward in our U.S. commercial strategy." He noted that Orthocell can now directly engage surgeons within military and VA systems while leveraging its existing distribution network.

His comments reinforce a company increasingly focused on execution and scaling its commercial presence in the U.S.

Foolish bottomline

This is clearly a positive announcement by Orthocell but execution remains key. Approval does not guarantee an easy pathway to commercialisation, and adoption will depend on surgeon uptake and sales effectiveness.

Still, Orthocell appears to be moving in the right direction with the U.S. defence healthcare system potentially acting as a powerful launchpad for broader growth.

The post Orthocell shares soar 22% on landmark US breakthrough appeared first on The Motley Fool Australia.

That's because the team at Bell Potter has just initiated coverage on it with a bullish view.

Which small-cap ASX stock?

The stock that Bell Potter has been looking at is Orthocell Ltd (ASX: OCC).

It is a commercial-stage regenerative medicine company focused on developing and commercialising collagen-based medical devices and autologous cell therapies. These are for the repair and regeneration of bone and soft tissue.

Bell Potter believes the company's Remplir product has a significant opportunity and could be a key commercial driver. It explains:

Orthocell's investment case is anchored by Remplir, a collagen nerve wrap used in peripheral nerve repair that is differentiated by both design and commercial positioning. The product targets an underpenetrated market where clinical need persists and adjunct device usage remains low, creating room for a next-generation solution to gain traction as surgeon familiarity, evidence and commercial access continue to build.

In this context, Remplir has the potential to become the key commercial driver of the OCC story, with adoption supported by a large procedural opportunity rather than requiring aggressive incumbent displacement.

Commercial inflection underway

The broker also highlights that the small-cap ASX stock's commercial inflection is underway at a time that its balance sheet is very strong. It adds:

OCC has moved beyond regulatory promise and into early US commercial rollout, opening access to a US$1.6bn peripheral nerve repair market. The company enters this phase well-funded, with A$49.4m of cash following its 1H FY26 capital raise, and is pursuing a more hands-on go-to-market model that combines specialist distributors with internal oversight of medical education, KOL engagement and hospital access.

This approach should enable OCC to drive early adoption in a capital-efficient manner while retaining control over the key levers of VAC conversion and surgeon uptake. Although near-term cash burn is likely to remain elevated, we expect Remplir-led revenue growth and margin expansion to progressively improve operating leverage as rollout matures.

Big potential returns

According to the note, Bell Potter has initiated coverage on the small-cap ASX stock with a speculative buy rating and $1.15 price target.

Based on its current share price of 78 cents, this implies potential upside of almost 50% for investors over the next 12 months.

Commenting on its buy recommendation, the broker said:

We initiate coverage with a BUY (spec.) recommendation and A$1.15 valuation based on a risk-adjusted DCF, which we see as more appropriate than relative multiples given OCC's early-stage commercial profile and FY29 EBITDA break-even horizon.

Our valuation is driven primarily by Remplir's US rollout, leaving the key near-term proof points centred on distributor execution, VAC conversion, surgeon uptake and repeat procedure volumes. Beyond our base case, we see additional upside from broader geographic rollout and further indication expansion, including EU/UK approval and prostate nerve repair.

The post Bell Potter just put a buy rating on this exciting small-cap ASX stock appeared first on The Motley Fool Australia.

In early trade, the ASX All Ords stock is up 5% to 82 cents.

Why are Orthocell shares rising today?

The company's shares are pushing higher today following the release of an announcement that highlights the real-world use of its Remplir device in a conflict setting.

Remplir is a collagen nerve wrap used in the repair of peripheral nerve injuries. It provides compression-free protection to the nerve, generating an ideal microenvironment to aid nerve healing.

According to the release, the ASX All Ords stock's Remplir product has been used in 23 surgical procedures on injured soldiers in Ukraine.

The company confirmed that the procedures followed a humanitarian delivery of the device to Ukraine in April 2025, with surgeons now successfully using Remplir in both primary and secondary nerve repair operations.

The good news is that feedback from surgeons has been positive, supporting the clinical utility of the device.

Real-world validation in challenging environments

Management highlighted that this deployment demonstrates the practicality of Remplir in demanding conditions such as conflict zones.

The device is designed to connect, protect, and cap severed nerves resulting from trauma. Its portability, ease of use, and ability to be stored at room temperature make it well suited for use in military and emergency environments.

Importantly, Orthocell was able to train Ukrainian surgeons remotely via video, supported by its key opinion leader and Australian orthopedic surgeon, Dr Alex O'Beirne. The successful adoption of the product following remote instruction highlights its accessibility and ease of implementation in the field.

Defence opportunity emerging

The ASX All Ords stock believes this experience could open the door to further opportunities with defence organisations globally.

Orthocell intends to continue working with Ukrainian surgeons to monitor patient outcomes and collect clinical data where possible. This data is expected to support future discussions with defence and medical organisations around the world.

Commenting on the development, the company's managing director, Paul Anderson, said:

In a time where there are multiple global conflicts, the application of Remplir in trauma-related nerve injuries is highly relevant. The successful remote training of surgeons and subsequent use of the device across 23 patients reinforces its unique handling, transportability, and clinical utility as a leading collagen-based nerve repair solution.

The post Which exciting ASX All Ords stock is jumping on big news? appeared first on The Motley Fool Australia.

In morning trade, the small cap ASX share has risen 3% to $1.13.

Why is this small cap ASX share charging higher?

Investors have been buying the regenerative medicine company's shares following the release of a quarterly update.

According to the release, the small cap ASX share achieved record quarterly revenue of $3.2 million for the three months ended 31 December 2025. This was the seventh quarter in a row of record sales and represents a 7% increase over the previous quarter and a 45.2% increase on the prior corresponding period.

Importantly, this record revenue performance was primarily driven by increased market penetration in existing markets, particularly in Australia. Approximately $90,000 in Remplir U.S. sales were generated in December, which was in line with expectations.

North America entry

Management appears to believe that it won't be long until its US sales start to become more meaningful.

The small cap ASX share revealed that its early U.S. results indicate that its hybrid market entry strategy, combining specialist distributors with internal field leadership, is successful and delivering positive momentum.

It also notes that the anticipated growth in Remplir adoption by U.S. surgeons represents the potential for a strong increase in revenue going forward, with momentum expected to build through 2026.

In addition, growth in Remplir sales is expected to be further supported by its entry into the Canadian market. Following the recent appointment of a second Canadian distributor, initial sales are targeted for the March quarter of FY 2026. It expects market adoption to grow steadily throughout 2026.

The small cap ASX share also highlights that with $49.4 million in cash reserves, no debt, and an R&D tax incentive refund of approximately $3.0 million expected soon, it is well-positioned to drive rapid product adoption and deliver a step change in revenue in FY 2026.

Commenting on the quarter, Orthocell's CEO and managing director, Paul Anderson, said:

The seventh consecutive record revenue result for the December quarter is particularly pleasing, driven by strong performance in existing markets and early Remplir unit sales in the U.S. Early U.S. results show our hybrid market entry strategy, combining specialist distributors with internal field leadership, is successful and delivering positive momentum. With the U.S. momentum building and Canada coming online, we see significant upside as we replicate the successful Australia and Singapore approach on a larger scale in the U.S.

The post This exciting small cap ASX share just delivered its 7th consecutive record quarter appeared first on The Motley Fool Australia.

In morning trade, the ASX healthcare stock is up 7% to $1.09.

Why is this ASX healthcare stock jumping?

Investors have been buying the regenerative medicine company's shares after it announced the first commercial sales of its Remplir product in Hong Kong. Management notes that this marks a key milestone in its Asian growth strategy.

Remplir is a collagen wrap used in nerve repair surgery to improve regeneration of damaged nerves and patient outcomes.

According to the release, these initial sales follow the successful introduction of Remplir in Hong Kong, including its first surgical use and strong reception at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress.

The first sales were to MontsMed and provide immediate in-market availability and are expected to support multiple downstream sales as surgeons adopt the technology.

The ASX healthcare stock notes that Hong Kong represents a significant growth opportunity, serving as a strategic entry point into the Guangdong–Hong Kong–Macao Greater Bay Area (GBA). This is a rapidly developing healthcare market of approximately 100 million people.

Strongly positioned

Together with MontsMed, Orthocell is strongly positioned to drive market penetration through leading hospitals and specialist surgeons across the region.

To further accelerate commercial traction, Orthocell's recently appointed Asia Pacific commercial director will be active in market from the first quarter of 2026.

It highlights that working closely with MontsMed, the commercial director will support awareness-building initiatives, surgeon education, and the expansion of Remplir sales across Hong Kong, with broader responsibilities across Australia and Asia.

Commenting on the news, Orthocell's CEO and managing director, Paul Anderson, said:

First Hong Kong sales represent an important commercial milestone for Orthocell and a strong validation of Remplir's clinical value. We are well positioned to support MontsMed in driving adoption across leading hospitals in Hong Kong and the Greater Bay Area. We are executing our commercialisation strategy with discipline, and today's achievement marks another step forward in establishing Remplir as a new standard of care in peripheral nerve repair.

The company also notes that with ~$50 million in cash and no debt, it remains strongly funded and well-positioned to drive rapid product adoption and deliver a step change in revenue in FY 2026.

It also advised that the Remplir rollout in the US$1.6 billion US market continues to build momentum. It revealed that in-country representatives are working closely with distributors to gain hospital approvals, onboard surgeons, and establish active accounts.

The post Guess which ASX healthcare stock is jumping 7% on big news appeared first on The Motley Fool Australia.

At the time of writing, the ASX All Ords stock is up 7.5% to $1.08.

Why is this ASX All Ords stock jumping?

Investors have been buying the regenerative medicine company's shares this morning after it released a promising update.

According to the release, the company notes that the adoption of its Remplir product by Australian urologists is accelerating.

It highlights that the product is increasingly being used during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications from peripheral nerve injury.

So much so, Remplir has now been used in ~100 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery.

Why is this a big deal?

The ASX All Ords stock believes that using Remplir in nerve-sparing RARP presents a significant opportunity.

It estimates that this could expand its total addressable market in the United States from US$1.6 billion to approximately US$2 billion. This is based on an estimated ~115,000 prostatectomies performed annually in the country, the majority of which are conducted robotically.

In order to capitalise on this opportunity, Orthocell is establishing a commercialisation advisory board and investing in additional research to strengthen the scientific evidence base for this innovative peripheral nerve repair application, ahead of a targeted US product launch in the medium term.

In addition, it is collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia. This data will be released once compiled and will support the scientific foundation for formal product launch in existing approved markets.

The company also provided an update on its performance in the United States. It revealed that the Remplir rollout continues to track according to plan, with over 4,000 units now shipped into the United States.

Management highlights that the initial U.S. surgical cases continue to build with in-country representatives making significant progress working with distributors to gain hospital approvals, on-board surgeons, and establish active accounts.

Commenting on the news, the ASX All Ords stock's CEO and managing director, Paul Anderson, said:

We're thrilled to see Remplir being adopted by urologists in Australia for nerve-sparing prostate surgery, reflecting its broader potential in peripheral nerve protection and repair. This demonstrates the utility of the product and represents the potential for a meaningful step forward in improving patient outcomes following these complex surgeries.

The post Guess which All Ords stock is racing higher on big news appeared first on The Motley Fool Australia.

In morning trade, the ASX stock is down 7% to $1.33.

However, longer term shareholders won't be too downbeat. That's because the regenerative medicine company's shares were up 115% on a 12-month basis prior to today.

Why is this ASX stock sinking?

The catalyst for today's decline has been news that Orthocell has received firm commitments for a $30 million capital raising via an institutional placement. These funds are being raised at a 9.1% discount of $1.30 per new share.

According to the release, the ASX stock received significant international and domestic demand for the capital raising from institutional and sophisticated investors. This will see a number of US institutions join the register.

The company notes that following the completion of the placement it will emerge with well over $50 million in cash and no debt. As a result, it expects to be fully funded for its global commercialisation strategy.

Proceeds from the raising will be used to accelerate the US roll out of the ASX stock's flagship nerve repair product Remplir. It will also undertake clinical studies to commercialise the use of Remplir in the significant prostate cancer surgery market.

In addition, Orthocell plans to advance the commercialisation of pipeline products in tendon and ligament repair, expand capacity at its existing manufacturing facility, and invest in new applications and technologies in the regenerative medicine sector.

Growth continues

The release also notes that Remplir continues to rapidly grow revenue in existing markets, having achieved six consecutive quarters of record revenue. This reached $3 million in the September quarter, but without a material contribution from the US market.

Its rollout in the US$1.6 Billion US market, post FDA clearance in April, is currently well ahead of schedule and to be accelerated with the use of the placement funds.

Commenting on the placement, the ASX stock's  CEO, Paul Anderson, said:

We have built significant momentum in the commercialisation of Remplir and the funds from the capital raising will be focused on accelerating that process. We greatly appreciate the support we have received from new and existing institutional and high net worth investors and particularly welcome our new investors from the US. We see that as a significant endorsement of our strategy and progress to date as well as the near-term revenue that can be generated from the US market.

We have recently announced our sixth consecutive quarter of record revenue primarily from our existing markets of Australia and Singapore, and we continue to track ahead of schedule in our US rollout of Remplir. That means we're in a position of strength and our capital raising is all about driving our growth plans.

The post Up 115% in a year! Why is this ASX stock sinking today? appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are ending the week on a high:

Elders Ltd (ASX: ELD)

The Elders share price is up 2.5% to $7.44. This morning, analysts at Bell Potter retained their buy rating and $9.45 price target on this agribusiness company's shares. This was in response to news that the ACCC will not block its acquisition of Delta Agribusiness. It said: "The closing of the Delta transaction is clearly a positive development, given the elongated acquisition timeline and in isolation is expected to be ~10% EPS accretive on a PF25e basis. In addition, we see encouraging indicators heading into FY26e, with crop input prices (fertiliser and glyphosate tech), livestock prices (cattle, lamb and mutton) and wool prices all demonstrating double digit YOY gains."

Netwealth Group Ltd (ASX: NWL)

The Netwealth Group share price is up 5% to $32.45. This is despite Bell Potter cutting its valuation of the investment platform provider's shares this morning. In response to its quarterly update, the broker retained its hold rating with a trimmed price target of $30.00. It said: "We have marked-to-market FUA for the update and upgraded our EPS forecasts +2%. There are no other model changes. We think there is a pretty clear pathway for +20% revenue growth and estimate free cash margins of 30% which would present a similar environment to FY22-24 where the company traded closer to 30x forward EBITDA."

Orthocell Ltd (ASX: OCC)

The Orthocell share price is up 6% to $1.53. This follows the release of the regenerative medicine company's quarterly update. Orthocell reported revenue of $3 million for the three months, which is up 11% quarter on quarter. And while it still recorded an operating cash outflow of $3 million, its balance sheet remains strong with $27 million in cash reserves. Orthocell's CEO, Paul Anderson, said: "We have continued to build strong commercial momentum in the September quarter with another record quarter of sales revenue delivered primarily from Remplir sales in our existing markets in Australia and Singapore."

Syrah Resources Ltd (ASX: SYR)

The Syrah Resources share price is up 18% to 42.5 cents. This has been driven by news that China is putting export controls on graphite. The team at Macquarie Group Ltd (ASX: MQG) believes this is a re-rating catalyst and upgraded Syrah's shares to an outperform rating with a 70 cents price target (from 30 cents). It said: "We believe this restriction is a material positive event for SYR as it is uniquely positioned, boasting one of the world's largest natural graphite operations with production capacity of ~350ktpa and an 11.25ktpa AAM Vidalia facility that is ramping up. We see this as a re-rating event that is comparable to LYC and MP Materials."

The post Why Elders, Netwealth, Orthocell, and Syrah shares are charging higher appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:

Bravura Solutions Ltd (ASX: BVS)

The Bravura Solutions share price is up a further 11% to $3.33. Investors have been buying the wealth management software solutions provider's shares this week following the release of a guidance update. Bravura revealed that it now expects FY 2026 revenue to be between $265 million and $275 million. This is ahead of its previous guidance for revenue in line with last year's result of $256.8 million. Also upgraded was its EBITDA guidance, which is now expected to be between $55 million and $65 million. This compares favourably to its previous guidance of $50 million. Management advised that this upgrade was driven by continued strength in the British pound, higher levels of project revenue, and its continued focus on operational efficiency.

Dateline Resources Ltd (ASX: DTR)

The Dateline Resources share price is up 12% to 56 cents. This follows the release of a drilling update from the gold and rare earths explorer this morning. Managing director, Stephen Baghdadi, commented: "This is an exciting phase for Dateline as we ramp up a major drill program at Colosseum, which is instrumental in accelerating our bankable feasibility study and bringing us closer to production. By utilising our in-house diamond rig alongside Major Drilling's high-powered RC rig, we can significantly increase the pace and scope of drilling, allowing us to tackle mineral resource infill, geotechnical work, and new target testing all at once."

Orthocell Ltd (ASX: OCC)

The Orthocell share price is up 5% to $1.51. This has been driven by the release of a sales update from the regenerative medicine company. Orthocell delivered record quarterly revenue of $3 million for the quarter ended 30 September. This represents a 9.1% increase over the previous quarter, which marks the sixth consecutive quarter of record revenue. This was driven primarily by increasing market penetration of nerve repair product Remplir in Australia and Singapore.

Race Oncology Ltd (ASX: RAC)

The Race Oncology share price is up 40% to $4.35. Investors have been fighting to get hold of this biopharmaceutical company's shares after it released positive cancer research data. Managing Director, Dr Daniel Tillett, said: "The discovery (E,E)-bisantrene acts primarily by binding to G4-DNA and RNA structures, and not like the chemotherapeutic doxorubicin, fundamentally changes our thinking on how to best use this drug in the clinic. Bisantrene continues to surprise, and we look forward to building on this mechanism of action discovery in our future clinical and commercial plans."

The post Why Bravura, Dateline, Orthocell, and Race Oncology shares are storming higher appeared first on The Motley Fool Australia.

Shares in the regenerative medicine company closed yesterday trading for $1.435. In early morning trade on Thursday, shares are changing hands for $1.530 apiece, up 6.6%.

This sees the Orthocell share price up a whopping 273.2% since this time last year.

Here's what's stoking investor interest today.

ASX All Ords stock leaps on record results

Investors are bidding up the Orthocell share price following the release of the company's quarterly results for the three months to 30 September.

Among the highlights, the ASX All Ords stock achieved record revenue of $3 million for the quarter. Orthocell said this was driven by increasing market penetration of its nerve repair product Remplir in both Australia and Singapore.

The September revenue figure is up 9.1% from the company's previous quarterly record of $2.7 million, achieved in the June 2025 quarter.

And in a promising growth sign, this marks the sixth consecutive quarter of record revenue for Orthocell.

The ASX All Ords stock noted that the record revenue results are yet to include "material revenue" from its Remplir sales in the United States. The company expects US sales revenues to build during the December 2025 quarter and grow into the second half of the 2026 financial year (FY 2026).

Canada also presents a potential growth market, with Orthocell recently appointing its first Canadian distributor. The company is targeting initial sales from this region in the December quarter.

What did management say?

Commenting on the quarterly results boosting the ASX All Ords stock today, Orthocell CEO Paul Anderson said, "The record revenue result for the September quarter is a particularly pleasing result, given it has largely been achieved from our existing markets in Australia and Singapore."

He noted that the results are "a tangible confirmation that surgeons are growing increasingly comfortable using Remplir in nerve repair procedures".

Anderson added:

Our US Remplir rollout remains on target with early surgical cases having been successfully undertaken during the quarter. As expected, these cases represented a modest financial contribution in the September quarter, but we see significant upside in our revenue growth potential as US momentum builds, and Canada comes online.

This is the market entry plan we followed in Australia and Singapore, and we hope to replicate it on a far larger scale in the US.

The ASX All Ords stock ended the quarter with $27 million in cash and no debt.

The post Up 273% in a year, guess which ASX All Ords stock is leaping higher today on a new record appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:

Bellevue Gold Ltd (ASX: BGL)

The Bellevue Gold share price is up 3.5% to $1.15. This may have been driven by the release of a broker note from Ord Minnett this morning. According to the note, the broker has upgraded the gold miner's shares to a buy rating with an improved price target of $1.40. This implies further potential upside of 22% for investors over the next 12 months. In addition, the gold price hit a new record high overnight. This has driven the S&P/ASX All Ords Gold index 0.8% higher on Tuesday.

DroneShield Ltd (ASX: DRO)

The DroneShield share price is up a further 3.5% to $4.56. Investors have been scrambling to buy this counter drone technology company's shares this week thanks to some big industry news. That news was the European Union's Defence Commissioner saying that the bloc will build a drone wall along the eastern flank, integrating detection, tracking and interception to counter hostile UAVs. The European Union is making the move after recent airspace violations. Bell Potter notes that "further details are expected at early-October EU meetings in Copenhagen and Brussels."

Orthocell Ltd (ASX: OCC)

The Orthocell share price is up 17% to $1.46. This morning, this regenerative medicine company announced that it has appointed its first distributor in the US$75 million Canadian market for its nerve repair and regeneration device Remplir. Orthocell's CEO and managing director, Paul Anderson, said: "Securing our first Canadian distributor provides immediate access to key provinces and will build Remplir's profile as a next-generation nerve repair solution. This is a major step in accelerating Remplir's international growth and our team is looking forward to supporting Canadian clinicians in delivering improved patient outcomes."

Restaurant Brands New Zealand Ltd (ASX: RBD)

The Restaurant Brands NZ share price is up 59% to $4.30. This follows news that the New Zealand based quick service restaurant operator has received a takeover offer. Finaccess Restauración has tabled a cash offer of NZ$5.05 per share. Its suitor stated: "[T]he offer price of NZ$5.05 per ordinary share is the final and best price that we are willing to pay under the takeover offer and accordingly we will not increase the consideration payable under the offer."

The post Why Bellevue Gold, DroneShield, Orthocell, and Restaurant Brands NZ shares are rising today appeared first on The Motley Fool Australia.

In morning trade, the small cap ASX share is up over 8% to $1.35.

Why is this ASX share jumping on Tuesday?

Investors have been bidding the regenerative medicine company's shares higher this morning after it released a positive announcement.

According to the release, the small cap ASX share is pushing forward with the commercialisation of its nerve repair and regeneration device Remplir in the US$75 million Canadian market with the appointment of its first Canadian distributor.

It notes that exclusive distributorships have been secured for Alberta and British Columbia, with further appointments anticipated for additional provinces. This is to ensure broad coverage of the material Canadian nerve repair market.

It may not be long until the company is generating revenue in the market. It revealed that official launch activities will commence in early October at the prestigious Annual Meeting of the American Society for Surgery of the Hand (ASSH) in Vancouver.

And the good news for this small cap ASX share is that its Canadian distributor has a wealth of expertise in nerve, spine and orthopaedic implant distribution. It also has established networks and a strong reputation in the local healthcare sector, which it believes will help drive product adoption.

It also believes it has the balance sheet strength to do this. Management notes that with around $27.5 million in cash and no debt, it is "well-positioned to drive rapid product adoption to deliver a step change in revenue in FY26."

Orthocell's CEO and managing director, Paul Anderson, was pleased with the news. He said:

Securing our first Canadian distributor provides immediate access to key provinces and will build Remplir's profile as a next-generation nerve repair solution. This is a major step in accelerating Remplir's international growth and our team is looking forward to supporting Canadian clinicians in delivering improved patient outcomes.

Our existing US Marketing and Medical Education teams are ideally placed to oversee our Canadian market entry given the significant crossover between jurisdictions with many surgeons operating in both countries. We expect to see early surgical cases commence in Canada late this year.

Though, it is worth noting that Canada represents only a small slice of its total addressable market (TAM). Management estimates that Remplir has a US$1.6 billion opportunity in the United States alone.

The post Guess which ASX share is jumping 8% on big North American news appeared first on The Motley Fool Australia.

The ASX All Ords stock is currently up 10% to $1.21.

This follows the regenerative medicine company announcing a major new application for its flagship nerve repair device, Remplir.

ASX All Ords stock jumps on exciting news

According to the release, Australian urologists have begun using its Remplir product in nerve-sparing robotic-assisted radical prostatectomies (RARP). This is a common treatment for prostate cancer.

The company revealed that the device has already been used in about 40 surgical cases aimed at improving recovery of erectile function and urinary continence after surgery.

This marks a significant development because prostate surgery often results in damage to the neurovascular bundle surrounding the prostate. And despite advances such as robotic surgery, up to 80% of men experience erectile dysfunction and up to 35% suffer urinary incontinence after the procedure.

But by wrapping and protecting nerves during surgery, Remplir may reduce those risks.

Expanding a global market opportunity

The release reveals that the ASX All Ords stock believes the use of Remplir in prostate surgery has the potential to expand its total addressable market significantly.

It is already rolling out Remplir in the US, a market it estimates to be already worth US$1.6 billion, and early adoption is building momentum. Plans are also underway to accelerate launches in Canada and Europe.

With around 12,000 robotic prostate surgeries performed annually in Australia alone, the new application adds to Orthocell's existing presence in orthopaedics and reconstructive surgery.

And with approximately $27 million in cash and no debt, Orthocell believes it is well-positioned to drive rapid product adoption to deliver a step change in revenue in FY 2026.

The ASX All Ords stock's chief executive, Paul Anderson, believes the development underscores the versatility of the company's technology. He commented:

The use of Remplir in nerve-sparing robotic-assisted radical prostatectomy highlights the product's versatility and superior performance in the protection and reconstruction of damaged peripheral nerves. Surgeons across multiple specialties—including orthopaedics, plastic and reconstructive surgery, and now urology—are increasingly adopting Remplir to simplify procedures, minimise scarring, and improve functional recovery.

This represents a significant step forward in Remplir's organic expansion into broader peripheral nerve repair applications and has the potential to substantially increase the device's global total addressable market.

The post Guess which ASX All Ords stock is jumping 10% on exciting news appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

4DMedical Ltd (ASX: 4DX)

The 4D Medical share price is up a further 38% to $2.13. This respiratory imaging technology company's shares are rocketing again on Monday after it announced agreements with a leading global pharmaceutical company, Royal Melbourne Hospital, and Spectrum Medical Imaging to deploy its lung health analysis software. Management notes that the agreements, spanning to 2027, aim to support lung cancer screening, including the recently commenced National Lung Cancer Screening Program (NLCSP) in Australia, and improve lung health assessment. CEO and Founder, Andreas Fouras, said: "In parallel to our US efforts to bring CT:VQ to market, we are pleased to see progress on other products in the portfolio in countries where CT:VQ is yet to receive regulatory clearance."

DroneShield Ltd (ASX: DRO)

The DroneShield share price is up over 5% to $3.19. Investors have been buying this counter drone technology company's shares after they were added to the ASX 200 index at the September quarterly rebalance. DroneShield is one of nine ASX shares that will join the benchmark index when the market opens on 22 September. This news can boost volume on the buy side as it means index funds that track the ASX 200 will need to purchase shares. In addition, some fund managers have mandates that only allow them to buy shares from certain indices. This could open up DroneShield shares to them now.

Orthocell Ltd (ASX: OCC)

The Orthocell share price is up 5% to $1.19. This follows news that a new Remplir study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. The regenerative medicine company's CEO, Paul Anderson, said: "We are delighted with the interim results from our Remplir RWE Study, validating the superior Remplir clinical outcomes, previously published in a highly regarded, peer reviewed journal. This performance is why more than 200 surgeons across more than 165 hospitals are now using Remplir and these numbers continue to grow." Remplir is a nerve repair product.

Resolute Mining Ltd (ASX: RSG)

The Resolute Mining share price is up 4.5% to 73.2 cents. Investors have been buying this gold miner's shares following the release of an updated mineral resources estimate from its Doropo Gold Project in Cote d'Ivoire. The project now has a total Measured, Indicated and Inferred MRE of 114 Mt grading 1.19 g/t Au for 4.4 Moz, which is a 28% increase from the previous MRE of 3.4 Moz.

The post Why 4DMedical, DroneShield, Orthocell, and Resolute Mining shares are racing higher appeared first on The Motley Fool Australia.

That was slightly weaker than the benchmark S&P/ASX 200 Index (ASX: XJO) but still an impressive result.

The ASX 200 increased by 9.97% and provided total returns of 13.81%, according to S&P Global data.

The ASX All Ords represents the 500 largest listed companies in Australia by market capitalisation.

Among them, eight companies saw their share prices triple over the financial year.

Let's check them out.

The 8 triple-baggers of the ASX All Ords in FY25

For a stock to triple its value, it needs more than 200% share price growth. These eight ASX All Ords shares achieved just that.

1. Larvotto Resources Ltd (ASX: LRV)

ASX All Ords gold and antimony mining share Larvotto shot the lights out in FY25 with a stunning 479% share price growth.

The stock finished the year at 69.5 cents apiece.

Larvotto says its Hillgrove gold and antimony project in NSW is Australia's largest antimony deposit and the eighth largest in the world.

Antimony is a critical metal used in the production of military applications and solar panels.

2. Catalyst Metals Ltd (ASX: CYL)

Shares of ASX All Ords gold explorer Catalyst Metals rose by an astounding 362% to close at $5.22 apiece on 30 June.

Catalyst benefited from strong growth in the gold price, with the commodity rising to a record US$3,500.05 per ounce on 22 April.

3. Meeka Metals Ltd (ASX: MEK)

Another ASX All Ords gold share, Meeka Metals, leapt 333% to close out the year at 14.5 cents per share.

Meeka Metals is a junior gold and rare earths exploration company with a portfolio of projects across Western Australia.

4. Titomic Ltd (ASX: TTT)

Titomic is benefiting from the rising global defence investment theme, with its shares lifting 311% to 30 cents in FY25.

The company offers industrial-scale metal additive manufacturing solutions using its patented kinetic fusion cold spray technology.

The cold spray is used in the development and production of products for the aerospace, defence, and shipbuilding industries.

5. Elsight Ltd (ASX: ELS)

This ASX All Ords tech stock lifted 290% to close at $1.775 on 30 June.

Elsight develops communications technology for unmanned, autonomous systems used in defence, public safety, and commercial sectors.

6. Canyon Resources Ltd (ASX: CAY)

This ASX All Ords materials share rose 236% to close at 24.5 cents on 30 June.

Canyon Resources is a mineral exploration company specialising in high-grade bauxite resources for the global aluminium market.

7. Orthocell Ltd (ASX: OCC)

ASX All Ords healthcare share, Orthocell, rose by 231% to $1.175 on 30 June.

Orthocell is a regenerative biotech that develops therapies to repair soft tissue injuries and regenerate nerve and tendon tissue.

8. Catapult Group International Ltd (ASX: CAT)

This ASX All Ords tech share soared 210% to close at $5.86 per share on 30 June.

Catapult is a global sports data and analytics company.

It provides professional sporting teams with detailed real-time data to optimise athletes' performances. 

The post 8 ASX All Ords shares that tripled in value in FY25 appeared first on The Motley Fool Australia.